Verdict: Macter International Limited (PSX: MACTER) opened FY2027 with higher sales and a modestly better gross margin, but the benefit stopped at gross profit. Distribution and selling costs rose faster than revenue, finance cost increased, and consolidated profit after tax fell by about one-third. The quarter therefore shows continued commercial expansion but weaker operating leverage and cash conversion. The key question for the next two quarters is whether current selling investment produces durable revenue growth without keeping operating margins compressed.
Results at a glance
- Period and basis: three months ended 30 September 2026; unaudited consolidated results, with standalone figures also filed. All financial amounts below are consolidated and in PKR unless stated otherwise.
- Revenue: PKR 3.20 billion, up 11.7% from PKR 2.86 billion in the comparable quarter.
- Gross profit: PKR 1.47 billion, up 14.2%; gross margin improved to 46.1% from 45.1%.
- Operating profit: PKR 213.5 million, down 22.6%; operating margin fell to 6.7% from 9.6%.
- Profit before tax: PKR 159.4 million, down 34.1%. Profit after tax: PKR 95.9 million, down 34.0%.
- Earnings per share: PKR 2.10 versus PKR 3.22.
- Cash flow from operations: negative PKR 54.7 million versus positive PKR 213.7 million a year earlier.
- Dividend: the board announced no cash dividend, bonus issue, rights issue or other entitlement with these results.
AlphaGen model scores
These are AlphaGen model outputs, not figures reported by Macter: Alpha QoQ Score 13.77; TTM Performance Score 19.76; 3Y Business Perf Score 74.84; Sector Leadership Score 33.92.
What improved
The top line remained the clearest positive. Revenue increased by PKR 335.2 million year on year to PKR 3.20 billion. Cost of sales rose by a slower 9.7%, allowing gross profit to increase by PKR 182.8 million and the gross margin to expand by roughly 0.9 percentage point. That combination suggests the quarter was not simply nominal sales growth: Macter retained slightly more gross profit from each rupee of sales.
The current filing does not disclose product, price, volume, domestic/export or channel contributions, so it is not possible to attribute the improvement precisely. Earlier official management material, for the half year to December 2025, said growth then reflected local portfolio expansion, new launches in niche categories and higher export volumes, with a better mix supporting gross margin. Those comments provide business context, but they should not be treated as management’s explanation for the September 2026 quarter.
Macter continues to operate across a broad pharmaceutical portfolio spanning prescription, consumer and biological products. Its March 2026 corporate briefing highlighted launches in GLP-1 therapies, including TirzaTrim, while the company’s product page identifies TirzaTrim as a tirzepatide multi-dose pre-filled pen. This broadening can support future growth, but the quarter’s filing provides no product-level sales or profitability, so no claim can be made about how much any individual launch contributed.
Balance-sheet working-capital balances moved in a constructive direction in aggregate. Inventory fell by PKR 265.8 million from June to PKR 2.79 billion and trade receivables fell by PKR 130.2 million to PKR 1.11 billion. The current ratio improved slightly to about 1.84 times from 1.79 times. These changes reduce the amount tied up in stock and customers, although inventory remains the largest current asset and therefore still matters materially for liquidity quality.
What weakened / needs attention
The central issue was spending below gross profit. Distribution and selling expense increased by PKR 231.9 million, or 28.1%, to PKR 1.06 billion—more than the entire PKR 182.8 million increase in gross profit. As a share of revenue, distribution and selling expense rose to 33.1% from 28.8%. Administrative expense also increased 9.5% to PKR 192.2 million. Lower other expenses partly helped, but other income also declined.
This arithmetic explains the earnings deterioration without requiring an unsupported operating story. Revenue growth produced more gross profit, but the extra gross profit was more than absorbed by selling and distribution costs. Operating profit consequently fell PKR 62.4 million to PKR 213.5 million, and the operating margin contracted by about 3.0 percentage points to 6.7%. The filing does not identify whether the higher selling bill came from launch activity, field-force expansion, promotion, distribution commissions, freight, exports or another factor. Any company-specific explanation beyond the reported line items would be speculation.
Finance cost added a second pressure. It rose 60.0% to PKR 54.1 million from PKR 33.8 million. That increase, combined with lower operating profit, reduced profit before tax by PKR 82.6 million to PKR 159.4 million. Tax expense fell broadly with pre-tax earnings, leaving profit after tax down PKR 49.4 million at PKR 95.9 million. Net margin narrowed to 3.0% from 5.1%. Profit attributable to owners was PKR 96.4 million, while the non-controlling interest absorbed a small loss.
Sequentially, the opening quarter was also softer than the June 2026 quarter. Revenue was about 10.4% higher than the immediately preceding quarter, but gross margin fell from roughly 48.7% to 46.1%, operating profit declined about 40%, and profit after tax fell about 34%. Quarter-on-quarter comparisons can be affected by seasonality and year-end adjustments, so this is best read as evidence that revenue momentum alone did not protect profitability, not as a forecast for the full year.
Cash conversion was weak. Cash generated from operations before finance costs and taxes was PKR 144.2 million, down from PKR 346.4 million. After finance costs and taxes, net operating cash flow was negative PKR 54.7 million versus positive PKR 213.7 million. Capital expenditure was PKR 99.6 million. The company therefore relied on financing cash flows during the quarter, including a net increase in short-term borrowings, rather than funding investment entirely from internal cash generation.
Short-term borrowings increased by PKR 248.8 million from June to PKR 539.5 million. Including long-term financing and its current portion, gross financing was about PKR 1.35 billion at September, while cash and short-term investments totaled about PKR 120.2 million. On that consistent calculation, net debt increased by roughly PKR 187 million during the quarter. The decline in inventory and receivables did not translate into positive operating cash because trade and other liabilities fell sharply and cash was used for finance costs and taxes.
Longer-run context
Macter’s recent growth record remains stronger than this quarter’s earnings direction. AlphaGen’s financial history shows consolidated revenue rising from PKR 5.14 billion in FY2021 to PKR 12.17 billion in FY2026. Full-year profit after tax rose from about PKR 257 million to PKR 675 million over that span, although FY2026 profit was below FY2025’s PKR 787 million. The September quarter therefore looks less like a sales-growth break and more like a continuation of the margin and cost-control challenge already visible in the latest full year.
The company’s official March 2026 briefing described manufacturing across sterile parenterals, inhalation products, tablets, capsules, ointments, liquids, injections and dry suspensions. That breadth creates multiple routes to growth but also demands selling investment, working capital and regulatory execution. The latest quarter does not disclose utilisation or current segment economics, so capacity and portfolio breadth should be treated as strategic context, not proof of near-term profit growth.
What to monitor next
- Distribution efficiency: whether selling and distribution expense grows slower than revenue, and whether the operating margin begins to recover from 6.7%.
- Gross-margin durability: whether the 46.1% margin holds as the sales mix changes, or whether the sequential decline from the June quarter persists.
- Product and export disclosure: management’s forthcoming quarterly report may clarify volumes, price/mix, launches and geographic contributions that the result announcement omits.
- Cash conversion: whether operating cash flow turns positive and whether inventory and receivables continue to fall without relying on lower supplier balances.
- Borrowings and finance cost: whether short-term debt normalises after rising PKR 248.8 million, and whether finance cost stops absorbing a larger share of operating profit.
- Capital expenditure: whether investment around manufacturing and biological products begins to generate measurable returns without further weakening free cash flow.
Evidence and limitations
Evidence coverage is pass with disclosed limitations. The exact company, period, unaudited basis, consolidated earnings, balance sheet, cash flow, EPS and board entitlement decision are verified in the official PSX result filing. Macter’s FY2026 audited report and March 2026 corporate briefing provide historical and strategic context. However, the nine-page result filing contains primary statements rather than detailed notes or a current management review. It does not disclose the September quarter’s product/segment, volume, pricing, channel or geographic split, nor the reason for the increase in distribution expense. Accordingly, this analysis explains the verified financial transmission and clearly labels older management context; it does not invent current-quarter causality.
Primary sources
Pakistan Stock Exchange: Macter International Limited result for the quarter ended 30 September 2026
Macter International Limited: Annual Report 2026
Macter International Limited: March 2026 Corporate Briefing Presentation